<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111061</article-id><article-id pub-id-type="publisher-id">ACM-40166</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_58543057.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  热毒宁、甘草酸苷联合治疗对第2期手足口病及其免疫细胞、炎性细胞因子的影响
  Combination Therapy of Reduning and Glycyrrhizin for the Second Stage of Hand, Foot and Mouth Disease and Its Immune Cells, and Inflammatory Cytokines
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>胜贤</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>罗</surname><given-names>杰平</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>丽珍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邓</surname><given-names>少芳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>庆华</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>叶</surname><given-names>潇鸣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>南宁市第二人民医院，广西 南宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>431</fpage><lpage>437</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨热毒宁、甘草酸苷联合治疗对第2期手足口病患儿的治疗效果、免疫细胞及炎性细胞因子的影响。方法：286例第2期手足口病患儿随机分成实验1组(66例)、实验2组(73例)、实验3组(72例)及实验4组(75例)，同期63例健康体检儿童作为对照组。治疗5 d后，观察HFMD患儿的临床疗效。应用流式细胞术检测研究对象外周血T淋巴细胞、Th细胞、Tc细胞、NK细胞和B淋巴细胞所占淋巴细胞的百分比。酶联免疫吸附法测定炎性细胞因子IL-6、IL-10.、TNF-ɑ水平，分析各组间上述指标的差异。结果：1) 较实验1组，实验2组、实验3组及实验4组的退热时间、皮疹消退时间、精神状态恢复情况或惊颤消失时间及危重型病例转化率明显降低，治疗效率显著升高，差异有统计学意义(P &lt; 0.05)，实验4组的正常体温恢复时间、皮疹消退时间、精神状态恢复情况或惊颤消失时间明显高于实验2组及实验3组(P &lt; 0.05)；2) 第2期手足口病患儿T淋巴细胞、Th细胞、Th/Tc细胞比值较对照组显著降低，而B淋巴细胞百分比、IL-6、IL-10和TNF-ɑ水平明显升高，差异有统计学意义(P &lt; 0.05)；3) 较实验1组，实验2组、实验3组及实验4组的T淋巴细胞、Th细胞、Th/Tc比值显著升高，B淋巴细胞及IL-6、IL-10.、TNF-ɑ的水平明显降低(P皆 &lt; 0.05)；且实验2组与实验4组的Th细胞、B淋巴细胞、Th/Tc比值、IL-6、IL-10.、TNF-ɑ间的差异有统计学意义(P &lt; 0.05)。结论：较单用热毒宁，热毒宁及甘草酸苷联合治疗能显著地改善第2期手足口患儿的临床症状和免疫功能紊乱，但热毒宁联合甘草酸苷改善免疫功能的作用较单独用药是否有叠加作用需进一步研究。
    Objective: To investigate the effect of Reduning combined with glycyrrhizin on immune cells and inflammatory cytokines in children with hand-foot-mouth disease (HFMD). Methods: 286 children with Stage II HFMD were randomly divided into the routine group (66 cases), the Reduning group (73 cases), the glycyrrhizin group (72 cases) and the combined group (75 cases), and 63 healthy children as the control group. After 5 days of treatment, the clinical therapeutic effect of HFMD children was observed. The percentage of T lymphocyte, Th cells, Tc cells, NK cells, and B lymphocyte in the lymphocyte of all subjects’ peripheral blood was measured by flow cytometry. Inflammatory cytokines IL-6, IL-10 and TNF-ɑ were measured by ELISA, to analyze the differences of the above indicators among the groups. Results: 1) Compared with the conventional treatment group, the time of antipyretic, the time of rash subside, the time of mental state recovery or the time of quiver subside and the conversion rate of critical cases were significantly decreased and the treatment efficiency was significantly increased (P &lt; 0.05). The recovery time of normal body temperature, the time of rash subside, the time of mental state recovery or the time of the shiver subsided in the combination group were significantly higher than those in the Reduning group and the glycyrrhizin group (P &lt; 0.05); 2) The ratio of T lymphocyte cells, Th cells and Th/Tc cells were significantly lower than those of the control group, but the percentage of B lymphocyte, IL-6, IL-10 and TNF-ɑ levels were significantly higher than those of the control group (P &lt; 0.05); 3) Compared with the conventional medication group, the T lymphocytes, Th cells, and Th/Tc ratios of the Reduning group, the glycyrrhizin group and the combined medication group were significantly increased, and the B lymphocytes and the level of IL-6, IL-10 and TNF-ɑ were significantly reduced (P &lt; 0.05); there were significant differences in Th cells, B lymphocytes, th/TC ratio, IL-6, IL-10 and TNF-α between the Reduning group and the combination group. Conclusion: Compared with the treatment of Reduning, Reduning and glycyrrhizin combined treatment can significantly alleviate the immune dysfunction in children with Stage II hand-foot-mouth disease; however, the effect of Reduning combined with glycyrrhizin on improving immune function should be further studied. 
  
 
</p></abstract><kwd-group><kwd>热毒宁，甘草酸苷，手足口病，免疫细胞，炎性细胞因子, Reduning</kwd><kwd> Glycyrrhizin</kwd><kwd> Hand-Foot-Mouth Disease</kwd><kwd> Immune Cells</kwd><kwd> Inflammatory Cytokines</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨热毒宁、甘草酸苷联合治疗对第2期手足口病患儿的治疗效果、免疫细胞及炎性细胞因子的影响。方法：286例第2期手足口病患儿随机分成实验1组(66例)、实验2组(73例)、实验3组(72例)及实验4组(75例)，同期63例健康体检儿童作为对照组。治疗5 d后，观察HFMD患儿的临床疗效。应用流式细胞术检测研究对象外周血T淋巴细胞、Th细胞、Tc细胞、NK细胞和B淋巴细胞所占淋巴细胞的百分比。酶联免疫吸附法测定炎性细胞因子IL-6、IL-10.、TNF-ɑ水平，分析各组间上述指标的差异。结果：1) 较实验1组，实验2组、实验3组及实验4组的退热时间、皮疹消退时间、精神状态恢复情况或惊颤消失时间及危重型病例转化率明显降低，治疗效率显著升高，差异有统计学意义(P &lt; 0.05)，实验4组的正常体温恢复时间、皮疹消退时间、精神状态恢复情况或惊颤消失时间明显高于实验2组及实验3组(P &lt; 0.05)；2) 第2期手足口病患儿T淋巴细胞、Th细胞、Th/Tc细胞比值较对照组显著降低，而B淋巴细胞百分比、IL-6、IL-10和TNF-ɑ水平明显升高，差异有统计学意义(P &lt; 0.05)；3) 较实验1组，实验2组、实验3组及实验4组的T淋巴细胞、Th细胞、Th/Tc比值显著升高，B淋巴细胞及IL-6、IL-10.、TNF-ɑ的水平明显降低(P皆 &lt; 0.05)；且实验2组与实验4组的Th细胞、B淋巴细胞、Th/Tc比值、IL-6、IL-10.、TNF-ɑ间的差异有统计学意义(P &lt; 0.05)。结论：较单用热毒宁，热毒宁及甘草酸苷联合治疗能显著地改善第2期手足口患儿的临床症状和免疫功能紊乱，但热毒宁联合甘草酸苷改善免疫功能的作用较单独用药是否有叠加作用需进一步研究。</p></sec><sec id="s2"><title>关键词</title><p>热毒宁，甘草酸苷，手足口病，免疫细胞，炎性细胞因子</p></sec><sec id="s3"><title>Combination Therapy of Reduning and Glycyrrhizin for the Second Stage of Hand, Foot and Mouth Disease and Its Immune Cells, and Inflammatory Cytokines<sup> </sup></title><p>Shengxian Huang, Jieping Luo, Lizhen Chen, Shaofang Deng, Qinghua Huang, Xiaoming Ye</p><p>The Second Nanning People’s Hospital, Nanning Guangxi</p><p><img src="//html.hanspub.org/file/61-1571857x4_hanspub.png" /></p><p>Received: Dec. 28<sup>th</sup>, 2020; accepted: Jan. 21<sup>st</sup>, 2021; published: Jan. 29<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/61-1571857x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the effect of Reduning combined with glycyrrhizin on immune cells and inflammatory cytokines in children with hand-foot-mouth disease (HFMD). Methods: 286 children with Stage II HFMD were randomly divided into the routine group (66 cases), the Reduning group (73 cases), the glycyrrhizin group (72 cases) and the combined group (75 cases), and 63 healthy children as the control group. After 5 days of treatment, the clinical therapeutic effect of HFMD children was observed. The percentage of T lymphocyte, Th cells, Tc cells, NK cells, and B lymphocyte in the lymphocyte of all subjects’ peripheral blood was measured by flow cytometry. Inflammatory cytokines IL-6, IL-10 and TNF-ɑ were measured by ELISA, to analyze the differences of the above indicators among the groups. Results: 1) Compared with the conventional treatment group, the time of antipyretic, the time of rash subside, the time of mental state recovery or the time of quiver subside and the conversion rate of critical cases were significantly decreased and the treatment efficiency was significantly increased (P &lt; 0.05). The recovery time of normal body temperature, the time of rash subside, the time of mental state recovery or the time of the shiver subsided in the combination group were significantly higher than those in the Reduning group and the glycyrrhizin group (P &lt; 0.05); 2) The ratio of T lymphocyte cells, Th cells and Th/Tc cells were significantly lower than those of the control group, but the percentage of B lymphocyte, IL-6, IL-10 and TNF-ɑ levels were significantly higher than those of the control group (P &lt; 0.05); 3) Compared with the conventional medication group, the T lymphocytes, Th cells, and Th/Tc ratios of the Reduning group, the glycyrrhizin group and the combined medication group were significantly increased, and the B lymphocytes and the level of IL-6, IL-10 and TNF-ɑ were significantly reduced (P &lt; 0.05); there were significant differences in Th cells, B lymphocytes, th/TC ratio, IL-6, IL-10 and TNF-α between the Reduning group and the combination group. Conclusion: Compared with the treatment of Reduning, Reduning and glycyrrhizin combined treatment can significantly alleviate the immune dysfunction in children with Stage II hand-foot-mouth disease; however, the effect of Reduning combined with glycyrrhizin on improving immune function should be further studied.</p><p>Keywords:Reduning, Glycyrrhizin, Hand-Foot-Mouth Disease, Immune Cells, Inflammatory Cytokines</p><disp-formula id="hanspub.40166-formula46"><graphic xlink:href="//html.hanspub.org/file/61-1571857x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/61-1571857x7_hanspub.png" /> <img src="//html.hanspub.org/file/61-1571857x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>手足口病(hand-foot-mouth disease, HFMD)是多种肠道病毒引起的，以发热、手足臀口腔出现疱疹或溃疡为主要临床症状的常见的婴幼儿急性传染病。因感染的肠道病毒类别不同，且患儿的状态特别是免疫功能的不同，HFMD患儿的临床症状呈现较大差异，大部分HFMD患儿仅表现出发热、足臀膝疱疹等症状，预后良好，而部分HFMD患儿除上述症状外，还表现出中枢神经系统损伤，继发严重的后遗症甚至危及生命 [<xref ref-type="bibr" rid="hanspub.40166-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40166-ref2">2</xref>]。有研究表明热毒宁、甘草酸苷均具有抗病毒、抗炎及提高免疫力的作用 [<xref ref-type="bibr" rid="hanspub.40166-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.40166-ref4">4</xref>]。本研究旨在探讨热毒宁、甘草酸苷对第2期HFMD患儿临床治疗效果、免疫细胞及炎性细胞因子的影响，及联合用药是否存在免疫调节作用的叠加情况，为临床治疗HFMD提供新的视角。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>2017年1月至2019年10月就诊于我院的第2期手足口病患儿(286例)为实验组，并按照电子表格随机数字分为四组，对照组为63例健康儿童，5组的年龄和性别无差异(P &gt; 0.05)。见表1。</p><p>HFMD患儿纳入研究标准：① 参照《肠道病毒71型(EV71)感染重症病例临床救治专家共识(2011版)》 [<xref ref-type="bibr" rid="hanspub.40166-ref5">5</xref>] 明确诊断的第2期HFMD患儿。根据疾病的发生、发展过程，将HFMD分为第1~第5期。第2期(神经系统受累期)，属于HFMD重症病例重型；② 患儿年龄 &lt; 14岁；③征得患儿监护人同意，并签订知情同意书。</p><p>排除标准 [<xref ref-type="bibr" rid="hanspub.40166-ref6">6</xref>]：① 有药物变态反应史者；② 合并其他心、肺、脑、血液系统等疾病者；③ 严重细菌感染者；④ 合并湿疹、水痘或口蹄疫等疾病者；⑤ 严重营养不良者；⑥ 依从性差，或者中途退出研究者。本研究经我院医学伦理委员会批准。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic information of research object</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n(例)</th><th align="center" valign="middle" >性别(男/女)</th><th align="center" valign="middle" >年龄(月)</th><th align="center" valign="middle" >平均年龄(月)</th></tr></thead><tr><td align="center" valign="middle" >II期HFMD患儿</td><td align="center" valign="middle" >286</td><td align="center" valign="middle" >157/129</td><td align="center" valign="middle" >5~84</td><td align="center" valign="middle" >36.9</td></tr><tr><td align="center" valign="middle" >实验1组</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >37/29</td><td align="center" valign="middle" >5~77</td><td align="center" valign="middle" >34.4</td></tr><tr><td align="center" valign="middle" >实验2组</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >39/34</td><td align="center" valign="middle" >7~76</td><td align="center" valign="middle" >36.9</td></tr><tr><td align="center" valign="middle" >实验3组</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >39/33</td><td align="center" valign="middle" >6~81</td><td align="center" valign="middle" >34.3</td></tr><tr><td align="center" valign="middle" >实验4组</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >42/33</td><td align="center" valign="middle" >6~84</td><td align="center" valign="middle" >35.7</td></tr><tr><td align="center" valign="middle" >健康对照组</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >35/28</td><td align="center" valign="middle" >10~81</td><td align="center" valign="middle" >38.3</td></tr></tbody></table></table-wrap><p>表1. 研究对象基本情况</p></sec><sec id="s6_2"><title>2.2. 治疗方案 [<xref ref-type="bibr" rid="hanspub.40166-ref6">6</xref>]</title><p>① 实验1组：该组HFMD患儿实施常规治疗:利巴韦林抗病毒治疗，以及退热、局部止痛、维持水电解质及酸碱平衡等对症治疗；</p><p>② 实验2组：该组HFMD患儿在实验1组治疗方案上，增加热毒宁注射液静脉滴注；</p><p>③ 实验3组：该组HFMD患儿在实验1组治疗方案上，增加复方甘草酸苷片口服治疗；</p><p>④ 实验4组：该组HFMD患儿在实验3组治疗方案上，给予热毒宁注射液静脉滴注。</p></sec><sec id="s6_3"><title>2.3. 临床疗效观察</title><p>连续用药5 d后观察各实验组治疗效果。临床治疗效果以HFMD患儿退烧、皮疹消退、惊颤消失、精神状态恢复情况、危重转化率情况等为观察指标。</p><p>疗效判断标准 [<xref ref-type="bibr" rid="hanspub.40166-ref6">6</xref>]：① 治愈：体温正常，皮疹消退，精神好，无精神系统损伤症状；② 有效：体温正常，皮疹减少，精神好转，惊颤次数减少；③ 无效：反复发热，皮疹无变化，频繁惊颤，意识障碍加重等。</p></sec><sec id="s6_4"><title>2.4. 免疫细菌及炎性细胞因子检测</title><p>抽取观察组患儿治疗5 d后、对照组儿童体检时的空腹静脉血约5 mL，注入EDTA-K<sub>2</sub>抗凝管和干燥管中，送至我院检验科，分别进行外周血免疫细胞及血清炎性细胞因子检测。具体如下。① 免疫细胞检测：应有流式细胞仪检测研究对象外周血中的T细胞，辅助T细胞(Th)，细胞毒性T细胞(Tc)，自然杀伤细胞(NK)和B细胞数量及其所占淋巴细胞的百分比。② 采用酶联免疫吸附法，测定外周血血清IL-6、IL-10、TNF-ɑ水平。</p></sec><sec id="s6_5"><title>2.5. 统计学分析</title><p>应用SPSS 22.0软件整理分析，Mean &#177; SD表示数据。计量资料的比较采用t检验或方差分析。P &lt; 0.05，表明差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 4组不同治疗方案的第2期HFMD患儿临床疗效观察指标比较</title><p>结果如表所示，4组不同治疗方案的第2期HFMD患儿临床疗效各指标有显著差异(P &lt; 0.05)。进一步组间比较，实验2组、实验3组和实验4组的临床疗效各指标较实验1组有差异(P &lt; 0.05)。实验4组的危重转化率较实验1组有显著差异(x<sup>2</sup> = 5.640, P = 0.018)。实验2组、实验3组和实验4组两两比较，部分临床疗效指标有明显差异(P &lt; 0.05)，危重转化率及总疗效略有差异，但差异无统计学意义(P &gt; 0.05).实验3组的退热起效时间虽略高于实验2组，但差异无统计学意义(P = 0.094)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The results of clinical curative effect observation indexes in children with stage 2 HFMD (Mean &#177; SD</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >免疫细胞</th><th align="center" valign="middle" >实验1组 (n = 66)</th><th align="center" valign="middle" >实验2组 (n = 73)</th><th align="center" valign="middle" >实验3组 (n = 72)</th><th align="center" valign="middle" >实验4组 (n = 75)</th><th align="center" valign="middle" >F(x<sup>2</sup>)值</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >退热起效时间(h)</td><td align="center" valign="middle" >11.28 &#177; 2.98</td><td align="center" valign="middle" >8.29 &#177; 2.34*</td><td align="center" valign="middle" >7.47 &#177; 2.85*</td><td align="center" valign="middle" >6.64 &#177; 2.39*<sup>#</sup></td><td align="center" valign="middle" >9.863</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >体温恢复正常时间(h)</td><td align="center" valign="middle" >53.83 &#177; 8.84</td><td align="center" valign="middle" >44.74 &#177; 5.66*</td><td align="center" valign="middle" >39.32 &#177; 5.32*<sup>#</sup></td><td align="center" valign="middle" >36.47 &#177; 5<sup>.27</sup>*<sup>#</sup></td><td align="center" valign="middle" >13.357</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >皮疹消失时间(d)</td><td align="center" valign="middle" >4.59 &#177; 0.45</td><td align="center" valign="middle" >3.63 &#177; 0.51*</td><td align="center" valign="middle" >3.32 &#177; 0.35*<sup>#</sup></td><td align="center" valign="middle" >3.04 &#177; 0.31*<sup>#</sup></td><td align="center" valign="middle" >21.073</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >危重转化率[n(%)]</td><td align="center" valign="middle" >7 (10.61)</td><td align="center" valign="middle" >2 (2.74)</td><td align="center" valign="middle" >2 (2.78)</td><td align="center" valign="middle" >1 (1.33)*</td><td align="center" valign="middle" >9.021</td><td align="center" valign="middle" >0.029</td></tr><tr><td align="center" valign="middle" >精神状态恢复或惊颤消失时间(d)</td><td align="center" valign="middle" >3.61 &#177; 0.44</td><td align="center" valign="middle" >2.99 &#177; 0.48*</td><td align="center" valign="middle" >2.82 &#177; 0.35*<sup>#</sup></td><td align="center" valign="middle" >2.46 &#177; 0.36*<sup>#</sup></td><td align="center" valign="middle" >16.359</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >疗效观察</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >治愈</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >32</td><td align="center" valign="middle"  rowspan="3"  >16.850</td><td align="center" valign="middle"  rowspan="3"  >0.010</td></tr><tr><td align="center" valign="middle" >有效</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >41</td></tr><tr><td align="center" valign="middle" >无效</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2</td></tr></tbody></table></table-wrap><p>表2. 第2期HFMD患儿临床疗效观察指标结果(Mean &#177; SD)</p><p>注：*：较实验1组比较，P &lt; 0.05；#：较实验2组比较，P &lt; 0.05。</p></sec><sec id="s7_2"><title>3.2. 第2期HFMD患儿组与健康对照组的免疫细胞及炎性细胞因子的水平比较</title><p>结果如表3所示，实验组的免疫细胞(除Tc细胞以外)及炎性细胞因子与对照组间有显著差异，差异有统计学意义(P皆 &lt; 0.05)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Results of immune cells and inflammatory cytokines in children with stage 2 HFMD and control group (Mean &#177; SD</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >T淋巴细胞</th><th align="center" valign="middle" >Tc细胞</th><th align="center" valign="middle" >Th细胞</th><th align="center" valign="middle" >Th细胞/Tc细胞</th><th align="center" valign="middle" >B淋巴细胞</th></tr></thead><tr><td align="center" valign="middle" >实验组</td><td align="center" valign="middle" >286</td><td align="center" valign="middle" >56.58 &#177; 10.36</td><td align="center" valign="middle" >18.72 &#177; 5.93</td><td align="center" valign="middle" >34.46 &#177; 7.25</td><td align="center" valign="middle" >1.84 &#177; 0.39</td><td align="center" valign="middle" >22.73 &#177; 4.93</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >63.34 &#177; 11.67</td><td align="center" valign="middle" >19.24 &#177; 5.27</td><td align="center" valign="middle" >39.82 &#177; 7.79</td><td align="center" valign="middle" >2.08 &#177; 0.47</td><td align="center" valign="middle" >20.82 &#177; 4.41</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.607</td><td align="center" valign="middle" >0.642</td><td align="center" valign="middle" >5.24</td><td align="center" valign="middle" >4.253</td><td align="center" valign="middle" >2.835</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.521</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.005</td></tr><tr><td align="center" valign="middle" >组别</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >NK细胞</td><td align="center" valign="middle" >IL-6 (ng/L)</td><td align="center" valign="middle" >IL-10 (ng/L)</td><td align="center" valign="middle" >TNF-ɑ (ng/L)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >患儿组</td><td align="center" valign="middle" >286</td><td align="center" valign="middle" >9.11 &#177; 2.23</td><td align="center" valign="middle" >24.02 &#177; 5.88</td><td align="center" valign="middle" >37.73 &#177; 5.42</td><td align="center" valign="middle" >3.83 &#177; 0.43</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >9.86 &#177; 2.26</td><td align="center" valign="middle" >13.34 &#177; 2.15</td><td align="center" valign="middle" >25.48 &#177; 4.68</td><td align="center" valign="middle" >1.32 &#177; 0.31</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.411</td><td align="center" valign="middle" >6.151</td><td align="center" valign="middle" >7.082</td><td align="center" valign="middle" >18.688</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.017</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. 第2期HFMD患儿与对照组的免疫细胞及炎性细胞因子的结果(Mean &#177; SD)</p></sec><sec id="s7_3"><title>3.3. 不同治疗方案的第2期HFMD患儿外周血免疫细胞的检测结果比较</title><p>结果如表4所示，不同治疗方案的第2期HFMD患儿外周血的免疫细胞(除Tc细胞以外)有显著差异(P皆 &lt; 0.05)。进一步组间比较，实验2组、实验3组和实验4组的免疫细胞(除Tc细胞以外)较实验1组有显著差异(P皆 &lt; 0.05)。实验4组的Th细胞、Th细胞/Tc细胞比值与实验2组有差异(P = 0.027; P = 0.019)，实验4组的Th细胞、Th细胞/Tc细胞比值虽略高于实验3组，但差异无统计学意义(P = 0.094; P = 0.073)。实验3组和实验4组的B淋巴细胞明显低于实验2组(P = 0.024; P = 0.013)。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Results of immune cell test in children with stage 2 HFMD treated with different regimens (Mean &#177; SD</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >T淋巴细胞(%)</th><th align="center" valign="middle" >Th细胞(%)</th><th align="center" valign="middle" >Tc 细胞(%)</th><th align="center" valign="middle" >Th细胞/Tc 细胞</th><th align="center" valign="middle" >NK 细胞(%)</th><th align="center" valign="middle" >B细胞(%)</th></tr></thead><tr><td align="center" valign="middle" >实验1组</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >51.28 &#177; 11.93</td><td align="center" valign="middle" >29.83 &#177; 6.84</td><td align="center" valign="middle" >18.59 &#177; 4.40</td><td align="center" valign="middle" >1.69 &#177; 0.32</td><td align="center" valign="middle" >9.08 &#177; 1.95</td><td align="center" valign="middle" >24.5 &#177; 5.3</td></tr><tr><td align="center" valign="middle" >实验2组</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >55.89 &#177; 9.34*</td><td align="center" valign="middle" >33.74 &#177; 7.66*</td><td align="center" valign="middle" >19.19 &#177; 4.66</td><td align="center" valign="middle" >1.81 &#177; 0.36*</td><td align="center" valign="middle" >9.09 &#177; 2.06</td><td align="center" valign="middle" >22.8 &#177; 5.2*</td></tr><tr><td align="center" valign="middle" >实验3组</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >57.21 &#177; 8.85*</td><td align="center" valign="middle" >35.32 &#177; 7.32*</td><td align="center" valign="middle" >19.06 &#177; 5.02</td><td align="center" valign="middle" >1.91 &#177; 0.38*</td><td align="center" valign="middle" >9.15 &#177; 2.43</td><td align="center" valign="middle" >21.9 &#177; 4.9*<sup>#</sup></td></tr><tr><td align="center" valign="middle" >实验4组</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >58.82 &#177; 9.93*</td><td align="center" valign="middle" >36.47 &#177; 7.27*<sup>#</sup></td><td align="center" valign="middle" >18.54 &#177; 4.61</td><td align="center" valign="middle" >1.97 &#177; 0.41*<sup>#</sup></td><td align="center" valign="middle" >9.17 &#177; 2.56</td><td align="center" valign="middle" >20.9 &#177; 5.6*<sup>#</sup></td></tr><tr><td align="center" valign="middle"  colspan="2"  >F值</td><td align="center" valign="middle" >3.673</td><td align="center" valign="middle" >4.364</td><td align="center" valign="middle" >0.947</td><td align="center" valign="middle" >2.869</td><td align="center" valign="middle" >0.958</td><td align="center" valign="middle" >2.963</td></tr><tr><td align="center" valign="middle"  colspan="2"  >P</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.122</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.103</td><td align="center" valign="middle" >0.011</td></tr></tbody></table></table-wrap><p>表4. 不同治疗方案的第2期HFMD患儿免疫细胞测定结果(Mean &#177; SD)</p><p>注：*：较实验1组比较，P &lt; 0.05；#：较实验2组比较，P &lt; 0.05。</p></sec><sec id="s7_4"><title>3.4. 不同治疗方案的第2期HFMD患儿血清中炎性细胞因子的检测结果比较</title><p>结果如表5所示，第2期HFMD患儿不同治疗方案间的血清炎性细胞因子IL-6、IL-10、TNF-ɑ水平有显著差异(P &lt; 0.05)。组间进一步比较，较实验1组，实验2组、实验3组和实验4组的免疫球蛋白IL-6、IL-10、TNF-ɑ有显著差异，差异有统计学意义(P &lt; 0.05)。实验4组的IL-6、IL-10、TNF-ɑ水平高于实验2组，差异有统计学意义(P = 0.027; P = 0.019; P = 0.026)，实验3组的IL-6、IL-10、TNF-ɑ水平较实验2组略低，但差异无统计学意义(P = 0.089; P = 0.074; P = 0.153)。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Detection of inflammatory cytokines in peripheral blood of children with stage 2 HFMD before and after treatment (Mean &#177; SD</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >炎性细胞因子</th><th align="center" valign="middle" >实验2组 (n = 73)</th><th align="center" valign="middle" >实验3组 (n = 72)</th><th align="center" valign="middle" >实验4组 (n = 75)</th><th align="center" valign="middle" >实验1组 (n = 66)</th><th align="center" valign="middle" >F值</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >IL-6 (ng/L)</td><td align="center" valign="middle" >25.89 &#177; 7.34*</td><td align="center" valign="middle" >23.74 &#177; 7.85*</td><td align="center" valign="middle" >22.82 &#177; 6.93*#</td><td align="center" valign="middle" >28.28 &#177; 2.78</td><td align="center" valign="middle" >6.735</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >IL-10 (ng/L)</td><td align="center" valign="middle" >39.74 &#177; 6.46*</td><td align="center" valign="middle" >37.72 &#177; 6.39*</td><td align="center" valign="middle" >35.64 &#177; 7.47*</td><td align="center" valign="middle" >41.83 &#177; 6.44</td><td align="center" valign="middle" >2.674</td><td align="center" valign="middle" >0.015</td></tr><tr><td align="center" valign="middle" >TNF-ɑ (ng/L)</td><td align="center" valign="middle" >4.39 &#177; 0.46*</td><td align="center" valign="middle" >3.71 &#177; 0.47*</td><td align="center" valign="middle" >3.64 &#177; 0.33*#</td><td align="center" valign="middle" >4.89 &#177; 0.37</td><td align="center" valign="middle" >2.725</td><td align="center" valign="middle" >0.013</td></tr></tbody></table></table-wrap><p>表5. 第2期HFMD患儿治疗前后外周血中炎性细胞因子的检测结果(Mean &#177; SD)</p><p>注：*：较实验1组比较，P &lt; 0.05；#：较实验2组比较，P &lt; 0.05。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>热毒宁是临床经常使用的中药注射剂，主要药材为金银花、栀子和青蒿。3味药材的相互协同，使得热毒宁具有退热、抗炎、抗病毒及提高免疫力的功效 [<xref ref-type="bibr" rid="hanspub.40166-ref3">3</xref>]。在临床使用中，热毒宁常与其他药物(如抗病毒药物、抗生素、糖皮质激素、肾上腺素等)联用，能显著缓解临床症状、缩短病程 [<xref ref-type="bibr" rid="hanspub.40166-ref3">3</xref>]。甘草酸苷是甘草的主要活性成分，研究表明具有抗炎、抗病毒、免疫调节以及抗肿瘤等多种功效 [<xref ref-type="bibr" rid="hanspub.40166-ref4">4</xref>]。尹翠红等 [<xref ref-type="bibr" rid="hanspub.40166-ref7">7</xref>] 研究表明甘草酸苷在消化道被β-D-葡萄糖醛酸糖苷酶进一步分解为18 β-甘草次酸，而18 β-甘草次酸的类皮质醇样结构，可抑制11 β-羟基固醇脱氢酶的活性，表现出皮质醇的功效，但不良反应却较常见的皮质醇少 [<xref ref-type="bibr" rid="hanspub.40166-ref8">8</xref>]。HFMD是肠道病毒引起的常见急性婴幼儿传染病，临床根据疾病进展过程可分为5期。第2期(神经系统受累期)患儿的临床症状除发热、手足口臀疱疹以外，还有嗜睡、吸吮无力、呕吐、体抖动、肌无力、颈强直项等中枢神经系统受损表现，此期病情进展快、凶险、易发展为危重症，但及时采取有效的治疗可痊愈 [<xref ref-type="bibr" rid="hanspub.40166-ref5">5</xref>]。当前临床治疗HFMD的重点和难点在于第2期HFMD的明确诊断和防止患儿由第2期向危重症发展的合理治疗 [<xref ref-type="bibr" rid="hanspub.40166-ref7">7</xref>]。有学者认为重症HFMD的发生与感染病毒的类别及患儿免疫功能密切相关，缓解免疫功能紊乱和抗病毒是防止第2期HFMD向危重症发展的主要措施 [<xref ref-type="bibr" rid="hanspub.40166-ref9">9</xref>]。</p><p>HFMD患儿不同治疗方案间的结果显示，不同治疗方案的第2期HFMD患儿临床治疗效果有明显差异。常规抗病毒治疗的基础上加入热毒宁或甘草酸苷的治疗，HFMD患儿临床症状明显改善，特别是热毒宁联合甘草酸苷的治疗效果更为显著，患儿危重型转化率亦明显低于常规抗病毒治疗，表明热毒宁、甘草酸苷能显著改善第2期HFMD的临床症状，联合应有能明显降低患儿危重症转化率。第2期HFMD患儿的免疫细胞和炎性细胞因子较健康儿童有明显差异。这与国内外学者的研究结论基本一致 [<xref ref-type="bibr" rid="hanspub.40166-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.40166-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.40166-ref12">12</xref>]，认为婴幼儿感染肠道病毒后，机体免疫系统启动，刺激非特异性免疫细胞和易感细胞释放各种细胞因子(如TNF-ɑ、IL-10等炎性细胞因子)，这些细胞因子进一步引导机体特异性或非特异性炎症的发生，使机体清除与抑制病毒，促进疾病痊愈。机体炎症反应的发生，与其相关的细胞因子随之发生变化，通过检测相关的细胞因子可以判断机体的炎性反应程度和间接判断免疫状况 [<xref ref-type="bibr" rid="hanspub.40166-ref11">11</xref>]。HFMD患儿感染初期，机体已通过多种途径激活免疫系统，重症化后，T细胞及NK细胞大部分已凋亡或处于功能障碍状态，引起固有免疫和细胞免疫紊乱。当细胞免疫不能有效抑制或杀灭病毒时，机体通过活化B细胞，启动体液免疫来参与抗病毒过程 [<xref ref-type="bibr" rid="hanspub.40166-ref13">13</xref>]。同时机体免疫功能紊乱时，大量促炎症细胞因子被释放，引起组织损伤，加重疾病，而这又进一步加剧炎症反应，产生大量炎性细胞因子 [<xref ref-type="bibr" rid="hanspub.40166-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.40166-ref14">14</xref>]。较常规抗病毒对症治疗的第2期HFMD患儿，单独或联合使用热毒宁、甘草酸苷治疗的患儿免疫细胞和炎性细胞因子显著差异，提示热毒宁、甘草酸苷能显著地提高第2期HFMD患儿T细胞及NK细胞数量，改善HFMD患儿的细胞免疫功能及固有免疫功能障碍状况，降低患儿炎性反应及抑制炎性细胞因子的释放。热毒宁联合甘草酸苷治疗的第2期HFMD的患儿Th 细胞百分比、Th细胞/Tc细胞比值较热毒宁治疗显著升高，炎性细胞因子明显降低。热毒宁联合甘草酸苷治疗的HFMD的患儿炎性细胞因子较甘草酸苷治疗略降低，Th细胞百分比、Th细胞/Tc细胞比值却略升高，但差异并无统计学意义。说明甘草酸苷、热毒宁联合在纠正第2期HFMD患儿免疫功能紊乱问题上较单用甘草酸苷无明显差异。这与我们的预期设想不一致，分析原因可能是热毒宁、甘草酸苷可能存在部分相同途径的免疫调节机制，两种药物竞争相同的药物受体，因此两种药物的免疫调节作用无叠加效果。但是否存在相同的免疫调节，需进一步研究。</p></sec><sec id="s9"><title>5. 结论</title><p>综上，较单用热毒宁，热毒宁联合甘草酸苷能显著地缓解第2期手足口患儿的临床症状和免疫功能紊乱，但热毒宁、甘草酸苷改善免疫功能的作用是否存在相同的免疫调节机制还需要进一步研究加以论证。</p></sec><sec id="s10"><title>基金项目</title><p>广西壮族自治区卫生计生委自筹经费科研课题(Z20170116)。</p></sec><sec id="s11"><title>文章引用</title><p>黄胜贤,罗杰平,陈丽珍,邓少芳,黄庆华,叶潇鸣. 热毒宁、甘草酸苷联合治疗对第2期手足口病及其免疫细胞、炎性细胞因子的影响Combination Therapy of Reduning and Glycyrrhizin for the Second Stage of Hand, Foot and Mouth Disease and Its Immune Cells, and Inflammatory Cytokines[J]. 临床医学进展, 2021, 11(01): 431-437. https://doi.org/10.12677/ACM.2021.111061</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40166-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Q., Zhou, M., Yang, Y., et al. (2019) Short-Term Effects of Extreme Meteorological Factors on Childhood Hand, Foot, and Mouth Disease Reinfection in Hefei, China: A Distributed Lag Non-Linear Analysis. Science of the Total Environment, 653, 839-848. &lt;br&gt;https://doi.org/10.1016/j.scitotenv.2018.10.349</mixed-citation></ref><ref id="hanspub.40166-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">国家卫生部手足口病临床专家组. 手足口病诊疗指南(2010年版) [EB/OL].  
http://www.chinanews.com/jk/news/2010/04-21/2240255.shtml, 2010-04-20.</mixed-citation></ref><ref id="hanspub.40166-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">赵慧, 王丽, 冷红春, 等. 热毒宁注射液治疗小儿胃肠型上呼吸道感染的效果观察[J]. 中华医院感染学杂志, 2016, 26(11): 2581-2583.</mixed-citation></ref><ref id="hanspub.40166-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">梁占捧, 李敬, 李舒, 等. 复方甘草酸苷片联合米诺地尔液治疗斑秃34例临床分析[J]. 中华实用诊断与治疗杂志, 2018, 32(12): 1216-1218.</mixed-citation></ref><ref id="hanspub.40166-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">国家卫生部手足口病临床专家组. 肠道病毒71型(EV71)染重症病例临床救治专家共识(2011年版) [EB/OL].  
http://www.nhc.gov.cn/yzygj/s3593/201105/203be457f36145058108fd818d9119db.shtml, 2011-05-13.</mixed-citation></ref><ref id="hanspub.40166-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">黄胜贤, 罗杰平, 陈丽珍, 等. 热毒宁联合甘草酸苷治疗II期手足口病及其免疫相关指标的改变[J]. 吉林医学, 2020, 8(41): 1809-1813.</mixed-citation></ref><ref id="hanspub.40166-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">尹翠红, 车雅敏. 复方甘草酸苷对T细胞相关细胞因子的影响[J]. 中华临床医师杂志(电子版), 2015, 9(22): 4124-4127.</mixed-citation></ref><ref id="hanspub.40166-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Q., Zhang, Q. and Hu, Z. (2019) Profiles of Human Enteroviruses Associated with Hand, Foot, and Mouth Disease in Nanjing, China. Disaster Medicine and Public Health Preparedness, 13, 740-744.  
&lt;br&gt;https://doi.org/10.1017/dmp.2018.155</mixed-citation></ref><ref id="hanspub.40166-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Li, H., Su, L., Zhang, T., et al. (2019) MRI Reveals Segmental Distribution of Enterovirus Lesions in the Central Nervous System: A Probable Clinical Evidence of Retrograde Axonal Transport of EV-A71. Journal of NeuroVirology, 25, 354-362. &lt;br&gt;https://doi.org/10.1007/s13365-019-00724-3</mixed-citation></ref><ref id="hanspub.40166-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Pei, X., Fan, X., Zhang, H., et al. (2019) Low Frequency, Weak MCP-1 Secretion and Exhausted Immune Status of Peripheral Monocytes Were Associated with Progression of Severe Enterovirus A71-Infected Hand, Foot and Mouth Disease. Clinical &amp; Experimental Immunology, 196, 353-363. &lt;br&gt;https://doi.org/10.1111/cei.13267</mixed-citation></ref><ref id="hanspub.40166-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Jiao, W., Tan, S.R., Huang, Y.F., et al. (2019) The Effectiveness of Different Doses of Intravenous Immunoglobulin on Severe Hand, Foot and Mouth Disease: A Meta-Analysis. Medical Principles and Practice, 28, 256-263.  
&lt;br&gt;https://doi.org/10.1111/cei.13267</mixed-citation></ref><ref id="hanspub.40166-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">王洁, 陈东, 赵昕峰, 等. EV71型手足口患儿免疫相关指标变化水平分析[J]. 中华医院感染学杂志, 2018, 28(14): 2197-2201.</mixed-citation></ref><ref id="hanspub.40166-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">潘招军. 手足口病患儿外周血CD56~(bright)和CD56~(dim)自然杀伤细胞的频率、表型和功能活性分析[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2019.</mixed-citation></ref><ref id="hanspub.40166-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Noisumdaeng, P., Korkusol, A., Prasertsopon, J., et al. (2019) Longitudinal Study on Enterovirus A71 and Coxsackievirus A16 Genotype/Subgenotype Replacements in Hand, Foot and Mouth Disease Patients in Thailand, 2000-2017. International Journal of Infectious Diseases, 80, 84-91. &lt;br&gt;https://doi.org/10.1016/j.ijid.2018.12.020</mixed-citation></ref></ref-list></back></article>